Gap junction beta-4 accelerates cell cycle progression and metastasis through MET-AKT activation in pancreatic cancer

Despite continuing advances in the development of effective new therapies, including immunotherapies, the prognosis of pancreatic Cancer remains extremely poor. Gap junction proteins have become attractive targets for potential Cancer therapy. However, the role of gap junction beta-4 (GJB4) protein remains unexplored in pancreatic Cancer. Through bioinformatic analyses we discovered pancreatic Cancer tissues showed higher levels of GJB4 transcripts compared to normal pancreatic tissues and this had a negative effect on overall survival in patients that had pancreatic Cancer. The high expression of nuclear GJB4 was identified as a negative prognostic factor in such patients. Knockdown of GJB4 in cultured pancreatic Cancer cells resulted in G₀ /G₁ arrest followed by decreased cell proliferation and suppression of metastatic potential. The overexpression of GJB4 accelerated cell proliferation, migration, and invasion in a SUIT-2 cell line, whereas Met Inhibitor canceled the acceleration. GJB4 suppression with siRNA significantly inhibited tumor growth in a mouse xenograft model. Mechanistically, suppression of GJB4 inhibited MET-AKT activities. Such data suggest that targeting the GJB4-MET axis could represent a promising new therapeutic strategy for pancreatic Cancer.

GJB4; MET-AKT; cell cycle arrest; metastasis; pancreatic cancer.